Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Santa Maria, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Santa Maria, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
St. Helena, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
St. Helena, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Stanford, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Stanford, CA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Newark, DE
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Newark, DE
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Orlando, FL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Orlando, FL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of Treasure Coast
mi
from
Port Saint Lucie, FL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Augusta, GA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Augusta, GA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Marietta, GA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Marietta, GA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Chicago, IL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chicago, IL
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Terre Haute, IN
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Terre Haute, IN
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Wichita, KA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Wichita, KA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Umass Memorial Medical Center
mi
from
Worcester, MA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Umass Memorial Medical Center
mi
from
Worcester, MA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
West Michigan Regional Cancer & Blood Center
mi
from
Freesoil, MI
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
West Michigan Regional Cancer & Blood Center
mi
from
Freesoil, MI
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Jackson, MS
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Jackson, MS
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Darien Pediatric Associates
mi
from
Darien, CT
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Darien Pediatric Associates
mi
from
Darien, CT
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Oncology & Hematology Associates
mi
from
Denville, NJ
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Oncology & Hematology Associates
mi
from
Denville, NJ
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
New York, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New York, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
New York, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New York, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
New York, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New York, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Rochester, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Rochester, NY
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Goldsboro, NC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Goldsboro, NC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Columbus, OH
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Columbus, OH
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Lancaster Cancer Center
mi
from
Lancaster, PA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Lancaster Cancer Center
mi
from
Lancaster, PA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Greenville, SC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Greenville, SC
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Memphis, TN
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Memphis, TN
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Lubbock, TX
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lubbock, TX
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
San Antonio, TX
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Antonio, TX
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Clinical Research Facility
mi
from
Seattle, WA
A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Seattle, WA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
AZD2171 and Whole Brain Radiation Therapy (WBRT) in Patients With Brain Metastases
A Phase I Study of AZD2171 and WBRT in Patients With Brain Metastases
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
University of Colorado Cancer Center - Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Washington University
mi
from
St. Louis, MO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Ohio State University
mi
from
Columbus, OH
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Ohio State University
mi
from
Columbus, OH
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
Sarah Cannon Cancer Center
mi
from
Nashville, TN
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
M. D. Anderson Cancer Center
mi
from
Orlando, FL
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
mi
from
Orlando, FL
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Phase 1 Study of ARRY-438162 (MEK162) in Patients With Advanced Solid Tumors Followed by Expansion Cohorts in Patients With Advanced or Metastatic Biliary Cancer or Metastatic Colorectal Cancer
Status: Archived
Updated: 1/1/1970
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Updated: 1/1/1970
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
St. Jude Heritage Healthcare
mi
from
Fullerton, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Updated: 1/1/1970
St. Jude Heritage Healthcare
mi
from
Fullerton, CA
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Randomized, Active-Controlled, Open-Label Phase 2 Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,